Erasca Initiates SEACRAFT-2 Pivotal Phase 3 Trial Evaluating Naporafenib Plus Trametinib In Patients With NRAS-Mutant Melanoma
Portfolio Pulse from Benzinga Newsdesk
Erasca, Inc. (NASDAQ:ERAS) has initiated the SEACRAFT-2 Phase 3 trial to evaluate the combination of naporafenib and trametinib in patients with NRAS-mutant melanoma. Naporafenib, a pan-RAF inhibitor, has shown favorable results in earlier trials and is being developed for multiple RAS/MAPK pathway-driven tumors. The trial's first stage results are expected in 2025.
June 18, 2024 | 12:05 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Erasca has initiated a pivotal Phase 3 trial for naporafenib in combination with trametinib for NRAS-mutant melanoma. The trial aims to build on promising results from earlier phases, with first stage results expected in 2025.
The initiation of a Phase 3 trial is a significant milestone for Erasca, indicating progress in their clinical development pipeline. Positive results from earlier trials suggest potential efficacy, which could drive investor optimism and positively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100